Long Ideas - After Bristol-Myers Squibb (NYSE:BMY) discontinued development of BMS-986094, once a promising nucleotide type drug for hepatitis C (HCV), in August, funds invested in this drug … Continue Reading
Read NowShort Ideas - Shares of Elan (NYSE:ELN) have been buoyed by two hopeful catalytic events, both of which appear to have gone away. As a result, this stock, … Continue Reading
Read NowShort Ideas - Discovery Laboratories (NASDAQ:DSCO) has moved up 28% on trading momentum following a Buy rating on the 24th. The company’s lead product, Surfaxin, was approved by … Continue Reading
Read NowShort Ideas - Alexza Pharmaceuticals (NASDAQ:ALXA) reported this morning that the company’s Adasuve manufacturing facility in Mountain View, CA received a Certificate of GMP (Good Manufacturing Practice) Compliance … Continue Reading
Read NowShort Ideas - Seattle Genetics (NASDAQ:SGEN) missed earnings expectations again, leaving analysts and investors uncertain about the company’s 2012 revenue guidance and beyond. Major shareholders may seek to … Continue Reading
Read NowShort Ideas - Shares of Seattle Genetics (NASDAQ:SGEN) have traded progressively higher this year, but tonight the rubber could meet the road if reported sales of lead cancer … Continue Reading
Read NowShort Ideas - ResMed (NYSE:RMD) reported revenues of $371.9 million and EPS of $0.53 for its fiscal fourth quarter (ended June), above Wall Street consensus estimates of $368 … Continue Reading
Read Now